In a world of rising healthcare costs, the greatest nightmare for payers is reimbursing drug interventions that do not meaningfully benefit their covered lives. Rare disease therapies, often viewed as attractive areas for pharmaceutical & biotech manufacturers, represent some of the most expensive interventions available today given inherently limited competition. Yet, as more manufacturers enter these spaces, the question for payers is how to ensure they are paying for the right therapy to allow rare disease patients to live fulfilling, healthy lives. How will payers tackle scary questions surrounding the cost of rare disease treatments? What is the impact of increasing competition in these spaces? What does this mean for manufacturers already playing in this space?
Join the Certara Evidence & Access team for a presentation on original research exploring these topics – and how you can be prepared for both the tricks – and the treats – of the scary future of rare disease management.